Accelerating a new era of
personalised therapies


The intelligent platform for precise, patient-centric drug development

Our cloud-based library of optical fingerprints, powered by photonics and AI, provides non-invasive tracking, screening and stratification for drug discovery, adapted to each clinical trial needs.

Efficient. Flexible. Patient-centric.

Minimally Invasive

Requires only microlitres of blood


Allows for label free flexibility on targets


Takes <10 seconds from start to finish

Low cost

Requires no consumables, only Light and AI

Advancing Drug Discovery For Alzheimer's Disease

How can we help?

Our blood-based screening test stratifies patients for clinical trials, removing heterogeneity due to pathophysiology, disease stage or degree of progression.

The iLoF Platform offers:

40% cost savings
70% reduction of time spent on screenings
A non-invasive process for patient convenience
A pool of more qualified candidates, improving trial outcomes

Paving the way for personalised medicine

One platform, endless posibilities.

With Alzheimer’s as a main focus, we are building out our virtual fingerprint library and bringing the power of our technology to other diseases


Forecasting clinical outcomes and predicting severity of symptoms

Gastric Cancer

Stratifying cancer subtypes allowing for design and delivery of tailored treatments


Differentiating between ischemic and hemorrhagic stroke patients for timely clinical management

Investors and Partners



United Kingdom

Oxford Foundry – University of Oxford
3-5 Hythe Bridge St
OX1 2EW Oxford

(+44) 01865 679064


Medical Research Center
R. Dr. Plácido da Costa
4200-450 Porto

(+351) 220 426 664